# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number:

k093280

# B. Purpose for Submission:

Addition of a new configuration cassette, including a new analyte, lactic acid; plus modification of the software to support change of the previously cleared OPTI CCATS analyzer (k993837)

# C. Measurand:

The new configuration cassette measures the following analytes:

Lactic acid, $\mathsf { p H }$ (hydrogen ion activity), $\mathsf { p C O } _ { 2 }$ (partial pressure of carbon dioxide), ${ \mathsf { p O } } _ { 2 }$ (partial pressure of oxygen), tHb (Hemoglobin), and $\mathrm { S O } _ { 2 }$ (Oxygen Saturation)

# D. Type of Test:

Quantitative: Optical fluorescence for Lactic acid, pH, $\mathsf { p C O } _ { 2 }$ and ${ \mathsf { p O } } _ { 2 }$ , reflectance for tHb and $\mathrm { S O } _ { 2 }$

# E. Applicant:

OPTI Medical Systems Inc.

OPTI CCA-TS B-Lac cassette

G. Regulatory Information:

<table><tr><td colspan="1" rowspan="1">Product Nomenclature</td><td colspan="1" rowspan="1">Regulation section</td><td colspan="1" rowspan="1">Classification</td><td colspan="1" rowspan="1">ProductCode</td><td colspan="1" rowspan="1">Panel</td></tr><tr><td colspan="1" rowspan="1">Electrode,Measurement of BloodGases (p02, pCO2)and Blood pH</td><td colspan="1" rowspan="1">21 CFR § 862.1120</td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">CHL</td><td colspan="1" rowspan="1">Chemistry(75)</td></tr><tr><td colspan="1" rowspan="1">Acid, Lactic, enzymaticmethod</td><td colspan="1" rowspan="1">21 CFR § 862.1450</td><td colspan="1" rowspan="1">Class I, meetslimitations ofexemptions per 21CFR 862.9 (c)(9)</td><td colspan="1" rowspan="1">KHP</td><td colspan="1" rowspan="1">Chemistry(75)</td></tr><tr><td colspan="1" rowspan="1">System, Hemoglobin,automated</td><td colspan="1" rowspan="1">21 CFR § 864.5620</td><td colspan="1" rowspan="1">II</td><td colspan="1" rowspan="1">GKR</td><td colspan="1" rowspan="1">Hematology(81)</td></tr><tr><td colspan="1" rowspan="1">Oximeter, whole blood</td><td colspan="1" rowspan="1">21 CFR § 864.7500</td><td colspan="1" rowspan="1">II</td><td colspan="1" rowspan="1">GLY</td><td colspan="1" rowspan="1">Hematology(81)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use statements below.

2. Indication(s) for use:

The OPTI CCA-TS B-Lac cassette is intended to be used for in vitro measurements of $\mathsf { p H }$ , $P \mathrm { C O } _ { 2 }$ , $P 0 _ { 2 }$ , lactate (lactic acid), total hemoglobin (tHb), and oxygen saturation $( \mathrm { S O } _ { 2 } )$ , in heparinized whole blood samples (either arterial or venous) on the OPTI CCA-TS system, in either a clinical setting or point-ofcare locations.

Measurements of blood gases $( P \mathrm { C O } _ { 2 } , P \mathrm { O } _ { 2 } )$ and blood $\mathsf { p H }$ are used in the diagnosis and treatment of life-threatening acid-base disturbances. Lactate (lactic acid) measurements that evaluate the acid-base status are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood). Total hemoglobin measurement is used to determine the hemoglobin content of human blood. Oxygen saturation measurements in conjunction with total hemoglobin measurement helps distinguish normal from abnormal states of blood volume in the detection of anemia and erythrocytosis.

3. Special conditions for use statement(s):

For prescription use only; for use in Point-of-Care settings; not for use with sodium flouride.

4. Special instrument requirements:

OPTI CCA-TS Analyzer

# I. Device Description:

The OPTI CCA-TS system is a portable $[ 4 . 7 \mathrm { ~ x ~ } 1 4 . 2 \mathrm { ~ x ~ } 9 . 1 $ inches, 12 pounds], microprocessor-based instrument using optical fluorescence for the measurement blood gases, electrolytes and enzymes and utilizes a graphical touch screen interface. There is an additional laser based measurement of total hemoglobin (tHb) and $\mathrm { S O } _ { 2 }$ capability available with any cassette that contains a ${ \mathsf { p O } } _ { 2 }$ sensor.

The OPTI CCA-TS B-Lac cassette is a disposable, single use cassette that contains four (4) sensors for in vitro measurements of $\mathsf { p H }$ , $\mathrm { P C O } _ { 2 }$ , $\mathrm { P O } _ { 2 }$ , and Lactate. The B-Lac cassette is sealed in a foil pouch along with a desiccant and is marked with a barcode label that includes a lot identification number, calibration information, and expiration date. The pH, pCO2, and pO2 are modified sensors from previously cleared wet storage type to dry storage type sensors. Total hemoglobin and oxygen saturation are the same as previously cleared in k984299.

The B-Lac cassette must be used in conjunctions with the OPTI CCA-TS analyzer.

# J. Substantial Equivalence Information:

1. Predicate device name(s): IL GEM Premier 4000 analyzer

2. Predicate K number(s): k061974

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">OPTI CCA-TS B-Lac cassette(Candidate device)</td><td colspan="1" rowspan="1">GEM 4000 analyzer(k061974-Predicatedevice)</td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Intended to be used for in vitromeasurements of pH, pCO2, pO2,lactic acid, tHb, and SO2 inheparinized whole blood, in either aclinical setting or point-of-carelocations.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analytes measure</td><td colspan="1" rowspan="1">pH, pCO2, pO2, lactic acid, tHb,and SO2.</td><td colspan="1" rowspan="1">Same, plus sodium,potassium, chloride,ionized calcium, glucose,total bilirubin</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Whole blood samples</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample volume</td><td colspan="1" rowspan="1">125μL</td><td colspan="1" rowspan="1">65-150μL</td></tr><tr><td colspan="1" rowspan="1">Measurement time</td><td colspan="1" rowspan="1">180 seconds</td><td colspan="1" rowspan="1">70-95 seconds</td></tr><tr><td colspan="1" rowspan="1">MeasurementPrinciple</td><td colspan="1" rowspan="1">pH: fluorescencePO2: fluorescencePCO2: fluorescenceLactic acid  Lactate oxidasebased fluorescent oxygen</td><td colspan="1" rowspan="1">pH: electrochemicalPO2: electrochemicalPCO2: electrochemicalLactic acid  Lactateoxidase based</td></tr><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">detectiontHb and SO2  Optical reflectancemeasurement.</td><td colspan="1" rowspan="1">amperometric peroxidedetectionHematocrit and CO-Oximetry - Opticalmeasurement ofhemoglobin andfractional derivatives ofhemoglobin in lysedblood</td></tr><tr><td colspan="1" rowspan="1">Reportable ranges</td><td colspan="1" rowspan="1">pH: 6.6 to 7.8PO2: 10-700 mmHgPCO2: 10-200 mmHgLactate: 0.3 to 17.5 mmol/LtHb: 5.0 - 25 g/dL</td><td colspan="1" rowspan="1">pH: 6.8 to 8.0PO2: 0-800 mmHgPCO2: 0-150 mmHgLactate: 0.1 to 20.0mmol/LtHb: 5.0 - 23.0 g/dL</td></tr></table>

# K. Standard/Guidance Document referenced (if applicable):

1. CLSI Guideline, EP5-A2 Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline Second edition (2004)   
2. CLSI Guideline, EP6-A Evaluation of the Linearity of Quantitative Analytical Methods; Approved Guideline (2003)   
3. CLSI Guideline, EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline- Second edition (2005)   
4. CLSI Guideline, EP9-A2 Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline Second edition (2002)

# L. Test Principle:

The single use B-Lac cassette contains a port that allows the introduction of a sample to an array of sensors sealed inside the cassette. The OPTI CCA-TS analyzer aspirates the sample from a capillary tube or syringe. The sensors use fluorescence optodes to measure the intensity of light emitted from fluorescent dyes exposed to specific analytes. The concentration of the analyte (pH, pCO2, pO2 and lactate) is determined by the calculation of the difference in fluorescence measured at a defined calibration point and that measured with the unknown concentration of analyte.

The lactate measurement is based on the enzymatic oxidation of lactate.

![](images/a62d8c67a01807a16ab84862bc83cbe306d5b29caf3acdea49102c79cee1ea61.jpg)

The sensor is constructed of an enzyme layer over an oxygen sensor. As a sample containing lactate contacts the sensor this enzymatic oxidation of the lactate consumes the oxygen locally present in the sensor. This decrease in oxygen is detected by the oxygen sensor. The amount of lactate is determined to be proportional to the rate at which the oxygen is consumed.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision study was designed based on the CLSI EP5-A2 guideline. The sponsor conducted within run precision and total precision with three levels of aqueous control materials (OPTI Check) on 3 lots of B-Lac cassettes. 12 cassettes were tested each day (4 each on three CCA-TS analyzers) at each control level over 20 days $\mathrm { ( N } = 2 4 0$ ). Results of the precision studies are shown below.

Table 1: Precision study results for control materials:   

<table><tr><td rowspan=6 colspan=10>OPTI Check Level 1pH       PCO2      PO2       tHb       SO2     LactateTotal Average     7.171      67.9      72.4      20.7      82.1      0.89Within Run St.Dev (Swr)     0.008        1.7        1.0        0.1        0.1      0.09Within Run %CV      0.1%      2.5%      1.4%      0.3%      0.1%    10.6%Total Precision St.Dev (St)     0.009        1.9        1.0        0.1        0.1      0.11Total %CV      0.1%      2.7%      1.4%      0.3%      0.1%    12.2%</td></tr><tr><td rowspan=1 colspan=1>7.171</td><td rowspan=1 colspan=1>67.9</td><td rowspan=1 colspan=1>72.4</td><td rowspan=1 colspan=1>20.7</td><td rowspan=1 colspan=1>82.1</td><td rowspan=1 colspan=1>0.89</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.09</td></tr><tr><td rowspan=1 colspan=1>6CV</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>10.6%</td></tr><tr><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.11</td></tr><tr><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>12.2%</td></tr><tr><td rowspan=6 colspan=10>OPTI Check Level 2pH       PCO2      PO2       tHb       SO2     LactateTotal Average     7.442      41.9     109.5      14.1      90.0      2.39Within Run St.Dev (Swr)     0.008        0.7        1.7        0.1        0.2      0.14Within Run %CV      0.1%      1.6%      1.5%      0.5%      0.3%      5.8%Total Precision St.Dev (St)     0.008        0.8        1.9        0.1        0.2      0.16Total %CV     0.1%     1.8%      1.7%      0.5%      0.3%      6.6%</td></tr><tr><td rowspan=1 colspan=1>7.442</td><td rowspan=1 colspan=1>41.9</td><td rowspan=1 colspan=1>109.5</td><td rowspan=1 colspan=1>14.1</td><td rowspan=1 colspan=1>90.0</td><td rowspan=1 colspan=1>2.39</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.14</td></tr><tr><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.16</td></tr><tr><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=7 colspan=10>OPTI Check Level 3pH       PCO2      PO2       tHb       SO2     LactateTotal Average     7.653      22.8     154.4        8.9      97.5      4.20Within Run St.Dev (Swr)     0.007        1.5        1.5        0.1       0.4      0.21Within Run %CV      0.1%      6.4%      1.0%      1.0%      0.4%      4.9%Total Precision St.Dev (St)     0.008        1.5        1.9        0.1        0.4      0.24Total %CV      0.1%      6.7%      1.2%      1.0%      0.4%      5.6%</td></tr><tr><td rowspan=1 colspan=1>7.653</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>154.4</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>4.20</td></tr><tr><td rowspan=1 colspan=1>r)</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.21</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=2 colspan=1>0.1%</td><td rowspan=2 colspan=1>6.4%</td><td rowspan=2 colspan=1>1.0%</td><td rowspan=2 colspan=1>1.0%</td><td rowspan=2 colspan=1>0.4%</td><td rowspan=2 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>b</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.24</td></tr><tr><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>5.6%</td></tr></table>

Additional within-run precision studies using whole blood samples drawn into heparinized tubes were conducted internally. For $\mathsf { p H }$ , $P 0 _ { 2 }$ , $P \mathrm { C O } _ { 2 }$ , and $\mathrm { S O } _ { 2 }$ whole blood was tonometered using different gas levels to give three different levels of measurements. For tHb, plasma was used to dilute the tHb measurement to achieve three different levels of tHb and samples were tonometered. Lactate blood samples were tonometered for 10 minutes using $6 \%$ CO2 / $12 \%$ O2 gas. A $5 0 0 \mathrm { m M }$ Sodium Lactate spike solution was prepared and used to increase the lactate values and produce three levels of lactate measurements. When testing precision in whole blood, two different sampling methods were used: syringe method and capillary method. In each method, six samples of whole blood were run on three lots of B-Lac cassettes. Lactate studies used six analyzers with one sample run on each analyzer in parallel with each lot. Total $\Nu = 1 8$ for each level. Results of the precision studies are shown below.

Table 2: Within-run precision study results using whole blood samples:   

<table><tr><td colspan="2"></td><td colspan="3"></td><td></td><td></td><td></td><td colspan="3"></td></tr><tr><td></td><td></td><td colspan="3">pHin Whole Blood</td><td></td><td></td><td></td><td colspan="3">SO2 (%) in Whole Blood</td></tr><tr><td colspan="2"></td><td colspan="3">Level 1 Level 2</td><td>Level 3</td><td colspan="3">Capillary Mbde</td><td>Level 1</td><td>Level 2</td><td>Level 3</td></tr><tr><td rowspan="5">Capillary Mbde</td><td>Average</td><td>7.157</td><td>7.298</td><td>7.614</td><td></td><td rowspan="11"></td><td></td><td>Average 71.2 St. Dev</td><td></td><td>95.5</td><td>99.9</td></tr><tr><td>St. Dev</td><td>0.011</td><td>0.010</td><td>0.013</td><td></td><td></td><td>14</td><td>0.3</td><td>0.0</td></tr><tr><td>%V</td><td>0.2%</td><td>0.1%</td><td>0.2%</td><td></td><td>%V</td><td>2.0%</td><td>0.3%</td><td>0.0%</td></tr><tr><td>Calculated Chi-Squared</td><td>5.0</td><td>4.3</td><td>7.1</td><td></td><td>Calculated Chi-Squared</td><td>16.6</td><td>0.3</td><td>0.0</td></tr><tr><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td><td></td><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td></tr><tr><td rowspan="5">Syringe Mbde</td><td>Average</td><td>7.170</td><td>7.306</td><td>7.610</td><td></td><td rowspan="5">Calculated Chi-Squared Allowed Chi-Squared</td><td>Average St. Dev</td><td>71.1 95.1</td><td>99.9</td></tr><tr><td>St. Dev</td><td>0.008</td><td>0.007</td><td>0.011</td><td>Syringe</td><td>1.6</td><td>0.3</td><td>0.0</td></tr><tr><td>%V</td><td>0.1%</td><td>0.1%</td><td>0.1%</td><td>Mbde</td><td>%V 2.2%</td><td>0.3%</td><td>0.0%</td></tr><tr><td>Calculated Chi-Squared</td><td>3.0</td><td>2.2</td><td>5.1</td><td></td><td>19.4</td><td>0.3</td><td>0.0</td></tr><tr><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td><td></td><td>26.3</td><td>27.6</td><td>27.6</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3"></td><td></td><td></td><td></td><td></td><td colspan="3"></td></tr><tr><td></td><td></td><td colspan="3">PCO2 (mmHg) in Whole Blood</td><td></td><td colspan="3">Mbde</td><td colspan="3">tHb (mg/dL) in Whole Blood Level 1 Level 2 Level 3</td></tr><tr><td rowspan="5">Capillary Mbde</td><td></td><td>Level 1 83.1</td><td>Level 2 413</td><td>Level 3</td><td></td><td rowspan="11"></td><td></td><td>Average 128</td><td>16.8</td><td></td><td>11.9</td></tr><tr><td>Average St. Dev</td><td>20</td><td>1.1</td><td>18.2</td><td></td><td rowspan="11"></td><td></td><td>0.2</td><td>0.4</td><td>0.3</td></tr><tr><td>%V</td><td>2.5%</td><td>2.7%</td><td>2.1</td><td>Capillary</td><td>St. Dev %V</td><td>1.8%</td><td>2.2%</td><td>2.7%</td></tr><tr><td>Calculated Chi-Squareo</td><td>6.4</td><td>3.4</td><td>11.4% 11.8</td><td></td><td>Calculated Chi-Squared</td><td>9.7</td><td>25.1</td><td>20.0</td></tr><tr><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td><td></td><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td></tr><tr><td rowspan="5">Syringe Mbde</td><td>Average</td><td>78.6</td><td>39.3</td><td>17.0</td><td></td><td rowspan="5"></td><td>Average</td><td>12.8</td><td>16.8</td></tr><tr><td>St. Dev</td><td>18</td><td>17</td><td>18</td><td>Syringe</td><td>St. Dev 0.3</td><td>0.2</td><td>12.0 0.3</td></tr><tr><td>%V</td><td>2.3%</td><td>4.4%</td><td>10.6%</td><td></td><td>%V 2.2%</td><td>14%</td><td>2.5%</td></tr><tr><td>Calculated Chi-Squared</td><td>5.8</td><td>8.1</td><td>8.8</td><td>Mbde</td><td>15.5</td><td>10.9</td><td>17.7</td></tr><tr><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td><td></td><td>Calculated Chi-Squared 27.6</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Allowed Chi-Squared</td><td></td><td>27.6</td><td>27.6</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">PO2 (mmHg) in Whole Blood</td><td></td><td></td><td colspan="4">Lactate (mmol/L) in Whole Blood Level 1 Level 2</td></tr><tr><td></td><td></td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td></td><td>Capillary Mbde</td><td></td><td>276</td><td>3.81</td><td>Level 3 4.83</td></tr><tr><td rowspan="5">Capillary Mbde</td><td>Average St. Dev</td><td>49.2 0.9</td><td>85.8 1.2</td><td>415.8</td><td></td><td rowspan="7">Syringe Mbde Allowed Chi-Squared</td><td>Average St. Dev</td><td>0.10</td><td>0.19</td><td>0.14</td></tr><tr><td>%V</td><td></td><td></td><td>8.6</td><td></td><td>%V</td><td>3.8%</td><td>5.0%</td><td>2.8%</td></tr><tr><td>Calculated Chi-Squared</td><td>18%</td><td>1.4%</td><td>2.1%</td><td></td><td>Calculated Chi-Squared</td><td>4.5</td><td>8.2</td><td>2.5</td></tr><tr><td></td><td>0.8</td><td>12</td><td>29</td><td></td><td>Allowed Chi-Squared</td><td></td><td></td><td></td></tr><tr><td>Allowed Chi-Squared</td><td>27.6</td><td>27.6</td><td>27.6</td><td></td><td>Average</td><td>19.7</td><td>19.7</td><td>19.7</td></tr><tr><td rowspan="5">Syringe Mbde</td><td>Average</td><td>48.4</td><td>83.3</td><td>398.8</td><td></td><td rowspan="5">Calcuated Chi-Squared</td><td>2.81 0.16</td><td>4.03</td><td>5.44</td></tr><tr><td>St. Dev</td><td>15</td><td>2.7</td><td>13.6</td><td></td><td>St. Dev</td><td>0.18</td><td>0.32</td></tr><tr><td>%V</td><td>3.1% 2.4</td><td>3.2% 7.1</td><td>3.4% 8.0</td><td></td><td>%V 5.6% 10.0</td><td>4.6% 6.7</td><td>5.9% 11.0</td></tr><tr><td>Calculated Chi-Squareo Allowed Chi-Squared</td></table>

Point-of-Care within-run precision study was performed at 2 point of care sites to demonstrate precision in the hands of the end users. Study from each site used two OPTI CCA-TS analyzers and 10 replicates of venous whole blood were assayed by potential end users. Results are shown in the tables below:

pH within run precision analysis of clinical samples

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>7.235</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>7.400</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>7.496</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.006</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.07%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.07%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.08%</td></tr></table>

$\mathrm { P C O } _ { 2 }$ within run precision analysis of clinical samples

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>28.1</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>40.7</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>70.9</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.80%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.05%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.58%</td></tr></table>

$\mathrm { P O } _ { 2 }$ within run precision analysis of clinical samples

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>39.6</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>97.9</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>189.0</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.45%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.50%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.89%</td></tr></table>

Lactate within run precision analysis of clinical samples tHb within run precision analysis of clinical samples

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>3.05</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>5.06</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.12</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>9.55%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>7.18%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.28%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>14.1</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>17.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.30%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.93%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.24%</td></tr></table>

$\mathrm { S O } _ { 2 }$ within run precision analysis of clinical samples   

<table><tr><td rowspan=1 colspan=2>level 1</td><td rowspan=1 colspan=2>level 2</td><td rowspan=1 colspan=2>level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>69.3</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>90.0</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>99.0</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.90%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.75%</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>0.07%</td></tr></table>

# b. Linearity/assay reportable range:

In-house linearity studies were performed in whole blood for the pH, $\mathrm { P C O } _ { 2 }$ , $\mathrm { P O } _ { 2 }$ , lactate, tHb and $\mathrm { S O } _ { 2 }$ measurements on the candidate device and on a FDA cleared method.

For the $\mathsf { p H }$ , $P \mathrm { C O } _ { 2 }$ and $P 0 _ { 2 }$ study, whole blood specimens from three different donors were tonometered with different $\% C O _ { 2 } / \% O _ { 2 }$ gas mixtures to generate samples with a range of values. Additional low $\mathsf { p H }$ sample points were generated by spiking whole blood with 0. 1 M HCl. For the tHb and $\mathrm { S O } _ { 2 }$ study, whole blood specimens were spun down to separate the plasma from the red blood cells. A range of tHb samples were then created by adding the plasma to the separated red blood cells in different volume combinations. These manipulated samples were tonometered with a $6 \%$ CO2 / $12 \%$ O2 gas mixture before measurement.

For lactate study, whole blood samples with concentrations distributed across a 0 to $2 0 \mathrm { m m o l / L }$ range were prepared and tested. Blank “blood” samples with no lactate were prepared by spinning down whole blood, removing the plasma fraction, washing the cells several times with isotonic buffer and then re-suspending the blood in the same buffer. Low lactate levels in blood were generated by addition of lactate oxidase to whole blood samples. Elevated levels of lactate were generated by spiking with either a $1 0 0 \mathrm { m M }$ or $5 0 0 \mathrm { m M }$ Lactate solution. A total of 13 different concentrations of lactate were tested with 4 replicates on the candidate device and duplicate on the predicate device.

The measured values are plotted against the expected values and linear regressions are generated and shown below with the sponsor’s claimed measuring ranges:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>pH</td><td rowspan=1 colspan=1>pCO2</td><td rowspan=1 colspan=1>pO2</td><td rowspan=1 colspan=1>Lactate</td><td rowspan=1 colspan=1>tHb</td><td rowspan=1 colspan=1>SO2</td></tr><tr><td rowspan=1 colspan=1>ClaimedMeasurement Range</td><td rowspan=1 colspan=1>6.6 to 7.8</td><td rowspan=1 colspan=1>10 to 200mmHg</td><td rowspan=1 colspan=1>10 to 700mmHg</td><td rowspan=1 colspan=1>0.3 to 17.5mmol/L</td><td rowspan=1 colspan=1>5 to 25g/dL</td><td rowspan=1 colspan=1>60 to 100%</td></tr><tr><td rowspan=1 colspan=1>TestedRange</td><td rowspan=1 colspan=1>6.59 to7.86</td><td rowspan=1 colspan=1>6.8 to205.4mmHg</td><td rowspan=1 colspan=1>6.8 to701.3mmHg</td><td rowspan=1 colspan=1>0 to 17.8mmol/L</td><td rowspan=1 colspan=1>4.98 -25.7 g/dL</td><td rowspan=1 colspan=1>54.1% -100.0%</td></tr><tr><td rowspan=1 colspan=1>Linearregressiongenerated</td><td rowspan=1 colspan=1>Y =0.99X +0.09</td><td rowspan=1 colspan=1>Y=1.00X+2.09</td><td rowspan=1 colspan=1>Y=0.98X- 0.68</td><td rowspan=1 colspan=1>Y=1.038 X+0.144</td><td rowspan=1 colspan=1>Y=1.00X+0.42</td><td rowspan=1 colspan=1>Y= 0.98X +2.25</td></tr><tr><td rowspan=1 colspan=1>$R{2}$</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>0.994</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The OPTI CCA-TS system is calibrated with methods traceable to NIST standards. Each lot of OPTI CCA-TS B-Lac cassettes is calibrated with standard solutions and gravimetrically-prepared gas mixtures traceable to NIST standards. Blood gas $P 0 _ { 2 }$ and $P C O _ { 2 }$ ) calibration uses multiple blood samples prepared by tonometry with certified gas mixtures traceable to NIST. pH calibration uses gravimetrically prepared standards measured on a reference instrument used as a secondary standard which is traceable to NIST standards. Lactate calibration uses gravimetrically prepared solutions verified with a legally marketed device since no NIST standard is available.

Real-time shelf life stability studies were performed on the B-Lac cassette design to demonstrate a maximum shelf life of 12 months at storage temperatures between 2 and 8 degrees C (refrigerated conditions) in unopened foil pouches. Stability after removal from storage at $2 { - } 8 ^ { \circ } \mathrm { C }$ and stored at room temperature up to $3 1 ^ { \circ } \mathrm { C }$ in sealed pouches was determined to be 14 days. Protocols and acceptance criteria were provided and found to be acceptable.

# d. Detection limit:

The sponsor determined that the detection limit was defined by the linear range study. The minimum detection limit is defined as the lowest analyte concentrations over the range that the assay has been shown to be acceptably linear. Please see linearity study in section M.1.b. above.

In addition, a limit of detection study was performed to evaluate the limit of detection for lactate according to CLSI EP17-A guideline. The lactate limit of detection evaluation was performed in whole blood. Whole blood “blank” samples were prepared by spinning down whole blood, removing the plasma fraction, washing the cells several times with isotonic buffer and then resuspending the blood in the same buffer. Low level samples with lactate concentrations were prepared from whole blood by diluting the plasma fraction with isotonic buffer. Testing was carried out on three different lots of B-Lac cassettes. The calculated $\mathrm { L o B } = 0 . 0 \ \mathrm { m m o l / L }$ and $\mathrm { L o D } = 0 . 1 7 \ \mathrm { m m o l / L }$ . The sponsor claimed that lactate has a measuring range of 0.3 to $1 7 . 5 \mathrm { m m o l / L }$ .

# e. Analytical specificity:

Interference study was designed according to CLSI EP7-A2 guideline to evaluate 15 different endogenous and exogenous substances. The study used human whole blood as the test material and was conducted for all the analytes at two concentration levels (normal and abnormal). For pH, pCO2, pO2, tHb and SO2 two different analyte levels were generated by tonometering with different gas mixtures. For lactate, the elevated level was generated by spiking with a lactate solution. All the samples were spiked with the potential

interferents (test samples) and were measured against the samples that were not spiked (control samples). The sponsor states that interferences are considered to be non-significant if the bias between the test and control samples are within $\pm 1 0 \%$ for lactate, $\pm 4 \%$ for $\mathsf { p C O } 2 , \pm 5 \%$ for O2, $\pm 0 . 0 2$ units for $\mathsf { p H }$ , $\pm 0 . 6 \mathrm { g } / \mathrm { d L }$ for tHb, and $\pm 3 \%$ for SO2. The tables below summarize the results of the interference testing performed. “No” significant interference is defined using the criteria listed above.

<table><tr><td rowspan=1 colspan=1>Interferencesubstances test</td><td rowspan=1 colspan=1>Highestconcentrationtested</td><td rowspan=1 colspan=1>pHinterference</td><td rowspan=1 colspan=1>pCO2(mmHg)interference</td><td rowspan=1 colspan=1>p02(mmHg)interference</td><td rowspan=1 colspan=1>Lactate(mmol/L)interference</td><td rowspan=1 colspan=1>tHb (g/dL)interference</td><td rowspan=1 colspan=1>SO2 (%)interferenc</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>1.66 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Acetyl-salicylicacid</td><td rowspan=1 colspan=1>3.33 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>0.23 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>B-hydroxybutyricacid</td><td rowspan=1 colspan=1>16.03 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.26 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Cardiogreen</td><td rowspan=1 colspan=1>0.0065mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Cystein</td><td rowspan=1 colspan=1>6.41 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>86.8 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Evans blue</td><td rowspan=1 colspan=1>0.0104mmol/L</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Glycolic acid</td><td rowspan=1 colspan=1>10 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Halothane</td><td rowspan=1 colspan=1>0.759 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>2.43 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Methylene Blue</td><td rowspan=1 colspan=1>0.125 mmol/L</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>SodiumChloride</td><td rowspan=1 colspan=1>20 mmol/L</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr></table>

The substances that were found to have significant interference were listed in the Operator’s manual.

In addition, sodium fluoride blood collection tubes were also tested and showed to interfere with the lactate sensor. Therefore, sodium fluoride is an unacceptable anti-coagulant to be used for the device. This limitation is stated in the Operator’s manual.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: A method comparison study intended to span the measuring range was performed internally with whole blood samples. Whole blood samples from multiple donors were tonometered with different $\%$ O2 and CO2 gas mixtures to generate a wide range of values. The blood samples were analyzed in parallel on the B-Lac cassette and other FDA cleared instruments. Results of the regressions analysis are summarized below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>pH</td><td rowspan=1 colspan=1>pCO2</td><td rowspan=1 colspan=1>pO2</td><td rowspan=1 colspan=1>Lactate</td><td rowspan=1 colspan=1>tHb</td><td rowspan=1 colspan=1>SO2</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>6.65-7.73</td><td rowspan=1 colspan=1>13.2 to195.9</td><td rowspan=1 colspan=1>13.0 to673.9</td><td rowspan=1 colspan=1>0.32- 16.9</td><td rowspan=1 colspan=1>6.4-23.8</td><td rowspan=1 colspan=1>73.2 -100.0</td></tr><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>0.99(0.98 to1.00)</td><td rowspan=1 colspan=1>1.00(0.99to1.02)</td><td rowspan=1 colspan=1>0.98(0.97 to0.99)</td><td rowspan=1 colspan=1>1.00(0.98 to1.02)</td><td rowspan=1 colspan=1>1.04(1.02 to1.04)</td><td rowspan=1 colspan=1>0.97(0.95 to0.98)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95%CI)</td><td rowspan=1 colspan=1>0.06 (-0.01 to0.12)</td><td rowspan=1 colspan=1>2.12(1.25to2.98)</td><td rowspan=1 colspan=1>-0.68(-3.87to2.52)</td><td rowspan=1 colspan=1>0.06(-0.13 to0.25)</td><td rowspan=1 colspan=1>-1.42(-1.81to -1.04)</td><td rowspan=1 colspan=1>3.25( 1.65 to4.85)</td></tr><tr><td rowspan=1 colspan=1>R^{2}$</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>0.995</td></tr></table>

In addition, method comparison studies were performed in multiple clinical sites with multiple point-of-care operators based on the CLSI EP9-A2 guideline. Excess blood aliquots from specimens collected for blood gas analyses was analyzed on a FDA cleared device depending on the clinical sites. Results were compared between the B-Lac cassettes on the OPTI CCATS analyzer (candidate method) and a FDA cleared device. Results are summarized below:

pH   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POC site 1</td><td rowspan=1 colspan=1>POC site 2</td><td rowspan=1 colspan=1>POC site 3</td><td rowspan=1 colspan=1>Combined allPOC sites</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>147</td></tr><tr><td rowspan=1 colspan=1>Range(mmol/L)</td><td rowspan=1 colspan=1>6.80-7.54</td><td rowspan=1 colspan=1>6.78-7.52</td><td rowspan=1 colspan=1>7.06-7.48</td><td rowspan=1 colspan=1>6.78-7.54</td></tr><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>0.94(0.92-0.96)</td><td rowspan=1 colspan=1>0.95(0.93-0.98)</td><td rowspan=1 colspan=1>0.92(0.88-0.97)</td><td rowspan=1 colspan=1>0.96(0.94-0.98)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95%CI)</td><td rowspan=1 colspan=1>0.45(0.29-0.61)</td><td rowspan=1 colspan=1>0.32(0.11-0.53)</td><td rowspan=1 colspan=1>0.57(0.24-0.90)</td><td rowspan=1 colspan=1>0.27(0.12-0.41)</td></tr><tr><td rowspan=1 colspan=1>$R^{2}$</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.98</td></tr></table>

pCO2   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">POC site 1</td><td colspan="1" rowspan="1">POC site 2</td><td colspan="1" rowspan="1">POC site 3</td><td colspan="1" rowspan="1">Combined allPOC sites</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">148</td></tr><tr><td colspan="1" rowspan="1">Range(mmol/L)</td><td colspan="1" rowspan="1">31 to 184</td><td colspan="1" rowspan="1">21 to 173</td><td colspan="1" rowspan="1">32 to 124</td><td colspan="1" rowspan="1">21 to 184</td></tr><tr><td>Slope (95%CI)</td><td>1.01 (0.99 - 1.04)</td><td>0.99 (0.95 -1.03)</td><td>0.96 (0.91 - 1.01)</td><td>0.99 (0.97 - 1.02)</td></tr><tr><td>Intercept (95%CI)</td><td>2.05 (0.26 - 3.85)</td><td>4.57 (1.48 -7.67)</td><td>6.7 (3.62 - 9.78)</td><td>4.15 (2.68 - 5.62)</td></tr><tr><td>$R^{}$</td><td>0.992</td><td>0.980</td><td>0.968</td><td>0.984</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POC site 1</td><td rowspan=1 colspan=1>POC site 2</td><td rowspan=1 colspan=1>POC site 3</td><td rowspan=1 colspan=1>Combined allPOC sites</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>148</td></tr><tr><td rowspan=1 colspan=1>Range(mmol/L)</td><td rowspan=1 colspan=1>38.0 to181.0</td><td rowspan=1 colspan=1>27.0 to288.0</td><td rowspan=1 colspan=1>37.0 to228.0</td><td rowspan=1 colspan=1>27 to 288</td></tr><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>1.08(1.04 to1.11)</td><td rowspan=1 colspan=1>1.08( 1.01 to1.15)</td><td rowspan=1 colspan=1>1.00(0.95 to1.05)</td><td rowspan=1 colspan=1>1.04(1.01 to 1.07)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95%CI)</td><td rowspan=1 colspan=1>-3.91(-7.40 to -0.41)</td><td rowspan=1 colspan=1>-5.78(-13.34 to1.78)</td><td rowspan=1 colspan=1>-0.22(-6.34 to5.90)</td><td rowspan=1 colspan=1>-2.76(-6.19 to 0.67)</td></tr><tr><td rowspan=1 colspan=1>$R^{}$</td><td rowspan=1 colspan=1>0.986</td><td rowspan=1 colspan=1>0.958</td><td rowspan=1 colspan=1>0.972</td><td rowspan=1 colspan=1>0.968</td></tr></table>

Lactate:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POC site 1</td><td rowspan=1 colspan=1>POC site 2</td><td rowspan=1 colspan=1>POC site 3</td><td rowspan=1 colspan=1>Combined allPOC sites</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>176</td></tr><tr><td rowspan=1 colspan=1>Range(mmol/L)</td><td rowspan=1 colspan=1>0.78-13.45</td><td rowspan=1 colspan=1>2.09-7.38</td><td rowspan=1 colspan=1>1.31-13.96</td><td rowspan=1 colspan=1>0.78-13.96</td></tr><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>0.94(0.87-1.01)</td><td rowspan=1 colspan=1>0.96(0.87-1.06)</td><td rowspan=1 colspan=1>0.93(0.86-0.99)</td><td rowspan=1 colspan=1>0.96(0.92-0.99)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95%CI)</td><td rowspan=1 colspan=1>0.02(-0.3 to0.34)</td><td rowspan=1 colspan=1>-0.12(-0.56 to0.32)</td><td rowspan=1 colspan=1>0.32(-0.19 to0.82)</td><td rowspan=1 colspan=1>-0.01(-0.21 to 0.20)</td></tr><tr><td rowspan=1 colspan=1>$R{}$</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.94</td></tr></table>

tHb   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">POC site 1</td><td colspan="1" rowspan="1">POC site 2</td><td colspan="1" rowspan="1">POC site 3</td><td colspan="1" rowspan="1">Combined allPOC sites</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">150</td></tr><tr><td colspan="1" rowspan="1">Range(mmol/L)</td><td colspan="1" rowspan="1">8.6 to 17.8</td><td colspan="1" rowspan="1">9.0 to 18.1</td><td colspan="1" rowspan="1">7.3 to 17.7</td><td colspan="1" rowspan="1">7.3 to 18.1</td></tr><tr><td colspan="1" rowspan="1">Slope(95%CI)</td><td colspan="1" rowspan="1">0.93(0.86 to1.00)</td><td colspan="1" rowspan="1">1.00(0.91 to1.09)</td><td colspan="1" rowspan="1">0.99(0.83 to1.14)</td><td colspan="1" rowspan="1">1.04(0.98 to 1.10)</td></tr><tr><td colspan="1" rowspan="1">Intercept(95%CI)</td><td colspan="1" rowspan="1">1.03(0.13 to1.94)</td><td colspan="1" rowspan="1">0.59(-0.56 to1.74)</td><td colspan="1" rowspan="1">0.42( -1.27 to2.11)</td><td colspan="1" rowspan="1">-0.13(-0.86 to 0.61)</td></tr><tr><td colspan="1" rowspan="1">R^2</td><td colspan="1" rowspan="1">0.924</td><td colspan="1" rowspan="1">0.912</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">0.908</td></tr></table>

SO2   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POC site 1</td><td rowspan=1 colspan=1>POC site 2</td><td rowspan=1 colspan=1>POC site 3</td><td rowspan=1 colspan=1>Combined allPOC sites</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>139</td></tr><tr><td rowspan=1 colspan=1>Range(mmol/L)</td><td rowspan=1 colspan=1>63.0 to 99.0</td><td rowspan=1 colspan=1>71.0 to100.0</td><td rowspan=1 colspan=1>68.0 to100.0</td><td rowspan=1 colspan=1>63 to 100</td></tr><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>1.07(1.00 to1.14)</td><td rowspan=1 colspan=1>0.90(0.83 to0.97)</td><td rowspan=1 colspan=1>1.04(1.01 to1.07)</td><td rowspan=1 colspan=1>1.02(0.99 to 1.05)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95%CI)</td><td rowspan=1 colspan=1>-5.77( -11.8 to0.25)</td><td rowspan=1 colspan=1>9.70(3.46 to15.94)</td><td rowspan=1 colspan=1>-3.74(-6.49 to -0.98)</td><td rowspan=1 colspan=1>-1.44(-4.54 to 1.66)</td></tr><tr><td rowspan=1 colspan=1>$R{}$</td><td rowspan=1 colspan=1>0.958</td><td rowspan=1 colspan=1>0.947</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>0.964</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The reference range for each parameter has been established in the literature. The sponsor cited the following literature for their reference range claim.

“Tietz, Burtis C, et al (Eds.), Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Ed., (Elsevier Saunders, 2006) pps. 2252-2302”.

N. Instrument Name: OPTI CCA-TS

# O. System Descriptions:

1. Modes of Operation: Single sample

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ___X_ __ or No

3. Specimen Identification: Manual sample identification

4. Specimen Sampling and Handling: Manual-syringe mode or capillary mode

5. Calibration:

Each lot of cassettes is calibrated during the manufacturing process and calibration information is coded onto the cassette. Prior to assaying a sample, calibration verification is performed using a precision gas mixture and the cassette’s internal storage buffer.

6. Quality Control:

Operator must initiate an external quality control procedure with manual injections of the quality control materials. Recommendations for frequency of testing are including in the labeling. As a minimum, users are to follow regulatory guidelines for testing quality control materials.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

Not applicable

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.